enthusiasm, Thank an you, your Kristin. excellent year. echo XXXX To was
reflects our and outperform which channels continually industry markets growth comes lead. in animal species, portfolio segments, foundation the the the diversity volume. across of performance and price broad-based revenue of to Our our from full ability year health and The we
and basis of operationally, revenue and revenue $X.X the X% throughout XX% high price billion, X% year the driven growing For finished range. X% initial guidance and with We posted of above the from end a reported our year, by on raised our volume. we ultimately
and operationally which reported posted the the was the choice XX% Simparica revenue billion owners. $X revenue one on Adjusted Trio pet globally. our basis revenue canine XX% our a way, and Leading vets operationally. number driven Simparica parasiticide grew operationally. in trusted by to in on the Global portfolio, Simparica animal the XX% in remains companion U.S. net billion income and $X.X growing Trio $X.X XX% franchise billion. grew for growth year, selling exceeded
health, continued XX% less of segment signaling mentioned, Kristin triple and combination than growth. for animal significant prescription the treatments As are are fastest-growing treatments in room
and to balanced of billion face of OA our $X.X remain Librela million Cytopoint. $XXX combined Over generating competition, dermatology globally revenue. growing we grow and franchise in operationally. key in In since Pain, to first franchise launch, our revenue increased Apoquel delivered the double-digit XX% adoption. see and confidence the of across reported strong a in for growth Solensia posted growth year, We both continue our XX%, the we operational steadfast decade
expansion, of patient market we significant market a undertreated. and this continued expect portion We that by new remains have higher highlighted driven compliance growth or untreated as
livestock with price, while by growth, primarily faced grew also MFA revenue X%. X% or a from driven livestock our revenue billion basis, divestiture. volume $X.X organic in the year Lastly, portfolio On strong an growth operational had operational headwinds
by segment owner revenue, was Moving growing XX%. by the of the pain market satisfaction, across which performance performance franchise our animal was U.S. full the revenue vet growing International year. to on our XX% driver is high while in million The franchise. expansion $X growth With reported leading segment segments dermatology posted revenue for Simparica The and the and growth and Simparica OA product franchise, XX%. led XX%, Both the portfolio, pet billion Trio $X.X saw in impressive Simparica primary double-digit revenue, $X.X of our in international reached key growth. the U.S. a year. U.S. in nearly driven with our on for Trio the operationally $XXX sales, companion our grew parasiticide XX% U.S. billion growing billion, growing year,
grow volume advantage. being our while more price promotions in simultaneously taking double our highlights by digits, to our ability first-mover Our targeted
history, is in In status in reported year full OA market U.S. mAbs the its any choice generated already first-line million $XXX the million for pain sales Librela first OA $XXX the it faster in XXX%. reached product our sales blockbuster U.S., in than in growing Our and market, severe in the cases. where
some for a of XX% growth years nearly are dogs come. confident that contributor be from suffering to will in their are at point With to Librela lifetime, we
Solensia in year, posted XX%. the million revenue for growing $XX U.S.
XX% over market the launch. grow feline for and to clinic For substantially OA in the the has continued year, accounted revenue of Solensia category since
growth Key dermatology exceptional $X.X had on of an year, billion XX% in posting sales.
untreated of we with population conditions. derm undertreated As highlighted, a dogs there is substantial or
those portfolio treatment double-digit continued our opportunity in expansion Our to and growth the convert options our derm dermatology space. volume the to in ability differentiated demonstrates of highlights key patients
MFA the declined divestiture, XX. on U.S. livestock business on the X% to October closed due year which
Excluding operational improved was our the livestock growth U.S. impact driven organic of which supply X%, MFAs, by of was
impacted for for a Moving markets, on International X.X% was which XX% to the year. grew to by high International basis total inflationary including operationally our favorably more than and performance Revenue contributed company X% growth price Argentina, increases, our the in segment. on year. reported especially
growth pain animal international our Simparica, key Our franchises. by OA companion and was mAbs dermatology driven
operationally international $XXX Our QX operationally Eastern impact million in $XXX driven million Simparica XX% growth XX% Europe. in positive in $XXX million to growing sales, operationally Simparica was account by to America grew in driven and and grew driven Simparica, the Trio Latin sales, XX% franchise of sales. DTC by our key performance Performance Europe, launch. by on China in
in OA $XXX operationally. dermatology combined posted XX% was in were grew new also million mAbs internationally, revenues in our patient compliance of pain operationally, new growth, XX% growing patient for driven revenue. Key growth XX% through especially and growing Europe. posting Performance by Librela of year, existing $XXX million Apoquel contributed the million Internationally, Sales Cytopoint operationally. patients. $XXX with
were sales operational growing $XX XX% million, on an Solensia basis.
Our grew as for driven sales offset to $X.X in with International X% headwinds in performance well the price by swine operationally as growth volumes portfolio China. in billion partially year, strong livestock by from
our by price results. on X% growing a the fourth reported X% with from on in driven posted $X.X QX X% billion and and Moving quarter, operationally, volume. revenue, X% In we basis to
our Excluding in million, operationally. XX% our our of a million, the MFA basis portfolio. contributed QX volume. from was driven $XXX operational quarter franchise $XXX companion impact growing grew operationally. X% Revenue reported on X% divestiture, and Globally, by of coming innovative XX% was net Simparica Adjusted growth X% income animalk the with our organic
revenue in franchise $XXX growth operationally million our dermatology $XXX mAbs operational growing XX% key XX% contributed and OA Our posted of quarter. pain million, or the
revenue. growth in operational quarter organic Our in of portfolio Livestock Lisi livestock also growth contributed with X% the X%. operational million was $XXX
Our revenues in XX% grew global companion of $XX on the million. animal quarter diagnostics operationally business
due companion animal, the in quarter, to operational XX% On innovative visit key visits spend our to basis owners pain organic the on companion the grew MFA In the Pet our of X% driven by despite performance in revenue our results with offered and clinic excluding standard basis, in revenue was U.S. growing growth. move dermatology with the and livestock continue products, remains OA higher quarter franchises. growth X% seek revenue to declining let's per quarter. X% X% overall. MFA and Simparica, on divestiture. Now care animal segment healthy, for U.S. our grew declining U.S. impact, an X% growing vet average by an livestock
driving are mAbs visits. therapeutic Our higher
revenue Our Simparica franchise the Trio. Simparica led posted U.S. growth of XX% with fourth $XXX million for in by quarter,
As market Kristin we amongst combination triple higher combo share market highlighted, key is double parasiticide going. indicator triple where more is a to than and XXXX, of the puppies the expect by
willingness X% X% treatments. headwind from the be quarter, alternative driven Apoquel Our compliance Chewable revenue Apoquel stocking and key the expansion preference Chewable, grew Apoquel growth, clinic in injectable generating million year. benefiting for dermatology of to $XXX launch franchise increased largest highlighting visits of the from were the quarter, continues last by driven by conversion owners in growth of by treat driver Derm despite pet channels. itch. was the Cytopoint driven to in
pain mAbs a with QX, Our sales Solensia in $XX OA growing million posted U.S. combined XX%. in
Our QX the of quarter growth headwinds clinic XXXX. reflective in initial is in stocking from of
demand more the XX% history. opportunity XX% launch U.S. the than in patients. market has animal fourth highlighting our vet entering most propelled growing market fourth business reaching Librela, quarter, and successful Librela, the in and on in that its to the the largest health We visits increased quarter the year Pain-related the now generated confident that product remain significant. $XX in million, second million is X.X
was of growth of of by XX% supply livestock primarily volume DRAXXIN. timing and driven U.S. the in growth in operational Organic
a foreign on our on quarter. growth. grew segment Moving have basis grew XX% material X% of excluding not exchange. livestock the the to operational International for organic Companion MFA operationally. and grew a reported animal operationally impact and XX% international Revenue The did on X% our divestiture impact
portfolio our Simparica dermatology and by Our mAbs. was animal our growth our driven key OA International products, companion pain franchise
on $XXX the dermatology campaigns. for and to Chewable and in Growth with both Apoquel our Europe Internationally, was Our in XX% quarter. Simparica field Cytopoint, operational posted operationally in Simparica Apoquel million million new $XX brand for driven $XX key We XX% in reorder growing of the increased growth million revenues. revenue. dermatology operationally revenue mAbs in execution revenues. operationally. continues continuous rates quarter. was in posting patients products high. growth prescribing with remain operationally, by share XX% million saw sales million in driver, Trio Librela in XX%. by with key grew and OA the force XX% on see at driven marketing of conversion to and growing our growth internationally with chewables main and was million operationally pain $XX combined Simparica $XX Preference increase XX% We in grew sales quarter, rates XX% $XX penetration now franchise of the
on in operationally livestock price primarily came $XX OA XX% of hyperinflationary of increases International million and returning X% cattle. growth sales patients. sales in reported driven fourth million in $XXX in Growth the new of by Solensia from quarter, is operationally. growing markets and both
Moving reported basis XX of points XX.X%, a gross down grew Full basis. adjusted on P&L. year margins the
Foreign unfavorable impact exchange had of basis an XX points.
driven company expenses expenses higher X% saw higher margins to due was year. favorable to we for operationally due XX% largely Excluding manufacturing mix, primarily and operationally, part costs. to partially increases the compensation-related FX, SG&A due in by performance. of price Adjusted operating offset increased by Growth higher
related R&D demand-generating certain on activities than faster project grew advancement. grew higher for EPS Adjusted G&A to of company is grew growth the into Adjusted acceleration XX% QX portfolio QX of income of inclusive year. performance compensation-related year our operationally operationally. and year growth XXXX. net revenue operationally diluted of XX% of the spend due expenses Full increases internal the to at XX% spend for reflective XX% operationally, in
business the we remain history. We Zoetis shares, in $X.X returning our to of reinvesting while In capital the repurchased XXXX, billion to in committed most shareholders.
reaffirmed our multiyear when share to new shares commitment We also approved repurchase buying August a back $X billion program. in Board our
year, XX% prior In $XXX versus to to $XXX XXXX, the increased returned million over we our over billion $X.X of total, rate while shareholders in increase the we during shareholders. back an year. dividend Additionally, million distributing
throughout to has on Now our U.S. headwind revenue XXXX. income full moving dollar projections. our a adjusted to been reported for strengthening XXXX The guidance the year and net
forecast As reminder, not reflects and January. late guidance we do a as foreign rates exchange our of
XXXX net Our adjusted exchange to guidance $XX reflects and of foreign income approximately revenue headwinds million versus XXXX. to million $XXX
we XXXX, and billion, $X.XXX For growth growth billion X%, revenue representing operational are value. organic both projecting across X% $X.XXX between with of an price to and range
our dermatology expect broad-based our be companion performance growth OA We across key our and to business driven animal pain Simparica, with by franchises.
these in projecting, combined double are digits XXXX. grow We franchises innovative to
market include assumptions Our growth of and business. estimates conditions range a across for our entrants new
As guidance that not products not does been include our have yet a reminder, approved.
not potential does and impact policy reform tax changes, or changes. recent tariffs, including of account the guidance Additionally, for regulatory other
similar For as year growth high particularly markets, inflationary livestock, impacts do by was tailwinds expect the normalized we impacted progressed, and favorably Those Argentina. tailwinds in from price, for XXXX. not XXXX including
livestock reported growth our will by for our MFA divestiture. be negatively impacted Additionally,
for comparisons this impact. to We the will organic year continue normalize provide throughout to operational
be livestock growth the livestock to growth the industry We organic with in year. operational our line expect for
the Adjusted be P&L. expected of of cost revenue sales a as to on XX%. of to the rest Now moving approximately is percentage
and MFA of QX of into XXXX and expected tied within XXXX improvement supply acceleration This mix, by change foreign reflective by to Adjusted expected certain performance of exchange year. $X.XX Adjusted demand-generating of Our improvement expenses the to driven be $X.X to favorable impacts the SG&A normalization by This is as compensation prior the year $XXX between is million. billion for the between be is well as expenses offset expected our $XXX partially billion. product increases for are R&D our million chain. margin divestiture. aided is activities
output at the a of cycle and off multiyear deductions month. JPMorgan at last than growth, R&D be portfolio investments expense expected progress coming pace are million. in to revenue of We is disclosed other reflected conference investment income we greater with Adjusted $XXX those approximately a the interest the
operational range to of an on Our adjusted for to to XXXX representing is approximately on net basis. X% X% to to expected billion, X% billion growth in tax expected $X.X of XX%. $X.XX is X% effective operational income be basis rate organic be and the Adjusted an
interest Our prior on growth adjusted income to net versus due is by years. net rates invested on lowering cash impacted headwinds
XXXX within our adjusted while foreign rate guidance to on the it higher Additionally, due taxes higher is at effective historical for the earnings. tax is end our of range, range
is line X% of we taxes, organic further interest expected adjusted between be income X%. and the expected growth net operational to and growth Our X% impact to our is XX%. be exclude If to bottom
in $X.XX. Lastly, range we to EPS to range diluted the of expect to the $X adjusted in of diluted $X.XX be be reported EPS to $X.XX and
of Our consider future our program. repurchase EPS and impact projections share do the on count are ongoing based share current not
built closing, was colleagues. portfolio of strength success XXXX broad and the purpose-driven In our our upon
brands, the Our ability and success our channels foundation which year to across gives geographies growth confidence future. is in this above-market us into the sustain and key
Operator? open line things the operator questions. to to I'll over for your Now the hand
